{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T03:34:35Z","timestamp":1789702475983,"version":"4.0.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001793","name":"Queensland University of Technology","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001793","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Triple Negative Breast Cancer (TNBC) is an aggressive subtype of breast cancer with limited treatment options and poor prognosis. Coupled with this, TNBC shows a high rate of metastasis which is known to be aided by tumour vasculature. Endothelial cells that form the lining of the tumour vasculature exhibit distinct genotype and phenotype differences compared with normal tissue vasculature. However, little is known about endothelial signatures that drive metastasis from a primary tumour, particularly in the context of immune infiltration. In this study, we utilized GeoMX Digital Spatial Profiling to investigate spatial proteomics differences in endothelial cells between primary and secondary sites of TNBC. By segmenting tissues using epithelial (PanCK), immune (CD45), and endothelial (CD31) markers, we analysed the microvasculature for a panel of 79 target proteins. In paired primary and secondary TNBC tissues, we identified significant downregulation of fibronectin (\u2212\u2009log2(Fold-Change) = \u2212\u20091.7,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001) in secondary sites. Specifically in epithelial regions, S100B was found to be downregulated in secondary microvasculature when compared to primary tumours. Additionally, metastasis-free primary tissues exhibited upregulated expression of S100B when compared to primary tissues that metastasized. Our study highlights the potential contributions of microvasculature to metastatic progression in TNBC, presenting new opportunities to explore them as potential biomarkers of TNBC metastasis.\n                  <\/jats:p>","DOI":"10.1007\/s10585-026-10391-4","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T03:31:55Z","timestamp":1768793515000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Digital spatial profiling identifies features of primary and locoregional metastatic vasculature in triple negative breast cancer"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4807-1150","authenticated-orcid":false,"given":"Akhilandeshwari","family":"Ravichandran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1101-8081","authenticated-orcid":false,"given":"Kyle","family":"Upton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8346-668X","authenticated-orcid":false,"given":"Shiva","family":"Taheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2148-4380","authenticated-orcid":false,"given":"Kaltin","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1906-5018","authenticated-orcid":false,"given":"Mark","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1174-0018","authenticated-orcid":false,"given":"Laura J.","family":"Bray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"10391_CR1","unstructured":"World Health Organization (2024) Breast cancer, https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer"},{"key":"10391_CR2","doi-asserted-by":"publisher","first-page":"479","DOI":"10.6004\/jnccn.2020.7554","volume":"18","author":"TE Keenan","year":"2020","unstructured":"Keenan TE, Tolaney SM (2020) Role of immunotherapy in triple-negative breast cancer. J Natl Compr Cancer Netw J Natl Compr Canc Netw 18:479\u2013489. https:\/\/doi.org\/10.6004\/jnccn.2020.7554","journal-title":"J Natl Compr Cancer Netw J Natl Compr Canc Netw"},{"key":"10391_CR3","unstructured":"American Cancer Society (2023) Triple-negative Breast Cancer, https:\/\/www.cancer.org\/cancer\/types\/breast-cancer\/about\/types-of-breast-cancer\/triple-negative.html"},{"key":"10391_CR4","doi-asserted-by":"publisher","unstructured":"Neophytou C, Boutsikos P, Papageorgis P (2018) Molecular mechanisms and emerging therapeutic targets of Triple-Negative breast cancer metastasis. Front Oncol 8. https:\/\/doi.org\/10.3389\/fonc.2018.00031","DOI":"10.3389\/fonc.2018.00031"},{"key":"10391_CR5","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.tranon.2016.07.002","volume":"9","author":"D Ribatti","year":"2016","unstructured":"Ribatti D et al (2016) Angiogenesis and antiangiogenesis in triple-negative breast cancer. Translational Oncol 9:453\u2013457","journal-title":"Translational Oncol"},{"key":"10391_CR6","doi-asserted-by":"publisher","first-page":"5917","DOI":"10.3390\/cancers13235917","volume":"13","author":"MR D\u2019Andrea","year":"2021","unstructured":"D\u2019Andrea MR et al (2021) Propensity for early metastatic spread in breast cancer: role of tumor vascularization features and tumor immune infiltrate. Cancers 13:5917","journal-title":"Cancers"},{"key":"10391_CR7","doi-asserted-by":"publisher","first-page":"4474","DOI":"10.7150\/jca.44313","volume":"11","author":"CO Madu","year":"2020","unstructured":"Madu CO, Wang S, Madu CO, Lu Y (2020) Angiogenesis in breast cancer Progression, Diagnosis, and treatment. J Cancer 11:4474\u20134494. https:\/\/doi.org\/10.7150\/jca.44313","journal-title":"J Cancer"},{"key":"10391_CR8","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","volume":"8","author":"Z-L Liu","year":"2023","unstructured":"Liu Z-L, Chen H-H, Zheng L-L, Sun L-P, Shi L (2023) Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Therapy 8:198. https:\/\/doi.org\/10.1038\/s41392-023-01460-1","journal-title":"Signal Transduct Target Therapy"},{"key":"10391_CR9","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/sj.bjc.6604929","volume":"100","author":"JA Nagy","year":"2009","unstructured":"Nagy JA, Chang SH, Dvorak AM, Dvorak HF (2009) Why are tumour blood vessels abnormal and why is it important to know? Br J Cancer 100:865\u2013869. https:\/\/doi.org\/10.1038\/sj.bjc.6604929","journal-title":"Br J Cancer"},{"key":"10391_CR10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrd3455","volume":"10","author":"P Carmeliet","year":"2011","unstructured":"Carmeliet P, Jain RK (2011) Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discovery 10:417\u2013427. https:\/\/doi.org\/10.1038\/nrd3455","journal-title":"Nat Rev Drug Discovery"},{"key":"10391_CR11","doi-asserted-by":"publisher","first-page":"a006536","DOI":"10.1101\/cshperspect.a006536","volume":"2","author":"AC Dudley","year":"2012","unstructured":"Dudley AC (2012) Tumor endothelial cells. Cold Spring Harb Perspect Med 2:a006536. https:\/\/doi.org\/10.1101\/cshperspect.a006536","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10391_CR12","doi-asserted-by":"publisher","first-page":"166985","DOI":"10.1016\/j.bbadis.2023.166985","volume":"1870","author":"A Ravichandran","year":"2024","unstructured":"Ravichandran A et al (2024) The in situ transcriptomic landscape of breast tumour-associated and normal adjacent endothelial cells. Biochim Et Biophys Acta (BBA) - Mol Basis Disease 1870:166985. https:\/\/doi.org\/10.1016\/j.bbadis.2023.166985","journal-title":"Biochim Et Biophys Acta (BBA) - Mol Basis Disease"},{"key":"10391_CR13","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/cas.12394","volume":"105","author":"T Otsubo","year":"2014","unstructured":"Otsubo T et al (2014) Identification of novel targets for antiangiogenic therapy by comparing the gene expressions of tumor and normal endothelial cells. Cancer Sci 105:560\u2013567. https:\/\/doi.org\/10.1111\/cas.12394","journal-title":"Cancer Sci"},{"key":"10391_CR14","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1146\/annurev-physiol-020518-114700","volume":"81","author":"JD Martin","year":"2019","unstructured":"Martin JD, Seano G, Jain RK (2019) Normalizing function of tumor vessels: progress, opportunities, and challenges. Annu Rev Physiol 81:505\u2013534. https:\/\/doi.org\/10.1146\/annurev-physiol-020518-114700","journal-title":"Annu Rev Physiol"},{"key":"10391_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40880-016-0083-5","volume":"35","author":"E Bugyik","year":"2016","unstructured":"Bugyik E et al (2016) Mechanisms of vascularization in murine models of primary and metastatic tumor growth. Chin J Cancer 35:19. https:\/\/doi.org\/10.1186\/s40880-016-0083-5","journal-title":"Chin J Cancer"},{"key":"10391_CR16","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1023\/A:1013139022051","volume":"18","author":"MJ Edel","year":"2000","unstructured":"Edel MJ, Harvey JM, Papadimitriou JM (2000) Comparison of vascularity and angiogenesis in primary invasive mammary carcinomas and in their respective axillary lymph node metastases. Clin Exp Metastasis 18:695\u2013702. https:\/\/doi.org\/10.1023\/A:1013139022051","journal-title":"Clin Exp Metastasis"},{"key":"10391_CR17","doi-asserted-by":"publisher","unstructured":"Jeong H-S et al (2015) Investigation of the lack of angiogenesis in the formation of lymph node metastases. JNCI: J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djv155","DOI":"10.1093\/jnci\/djv155"},{"key":"10391_CR18","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1080\/14728222.2022.2170779","volume":"26","author":"N Furukawa","year":"2022","unstructured":"Furukawa N, Stearns V, Santa-Maria CA, Popel AS (2022) The tumor microenvironment and triple-negative breast cancer aggressiveness: shedding light on mechanisms and targeting. Expert Opin Ther Targets 26:1041\u20131056. https:\/\/doi.org\/10.1080\/14728222.2022.2170779","journal-title":"Expert Opin Ther Targets"},{"key":"10391_CR19","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/s1470-2045(17)30904-x","volume":"19","author":"C Denkert","year":"2018","unstructured":"Denkert C et al (2018) Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 19:40\u201350. https:\/\/doi.org\/10.1016\/s1470-2045(17)30904-x","journal-title":"Lancet Oncol"},{"key":"10391_CR20","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1093\/annonc\/mdu112","volume":"25","author":"S Loi","year":"2014","unstructured":"Loi S et al (2014) Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 25:1544\u20131550. https:\/\/doi.org\/10.1093\/annonc\/mdu112","journal-title":"Ann Oncol"},{"key":"10391_CR21","doi-asserted-by":"publisher","first-page":"7441","DOI":"10.1245\/s10434-021-10227-3","volume":"28","author":"M Taskindoust","year":"2021","unstructured":"Taskindoust M et al (2021) Survival outcomes among patients with metastatic breast cancer: review of 47,000 patients. Ann Surg Oncol 28:7441\u20137449. https:\/\/doi.org\/10.1245\/s10434-021-10227-3","journal-title":"Ann Surg Oncol"},{"key":"10391_CR22","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/modpathol.2011.4","volume":"24","author":"RAA Mohammed","year":"2011","unstructured":"Mohammed RAA et al (2011) Lymphatic and blood vessels in basal and triple-negative breast cancers: characteristics and prognostic significance. Mod Pathol 24:774\u2013785. https:\/\/doi.org\/10.1038\/modpathol.2011.4","journal-title":"Mod Pathol"},{"key":"10391_CR23","doi-asserted-by":"publisher","unstructured":"Ayoub NM, Jaradat SK, Al-Shami KM, Alkhalifa AE (2022) Targeting angiogenesis in breast cancer: current evidence and future perspectives of novel anti-angiogenic approaches. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2022.838133","DOI":"10.3389\/fphar.2022.838133"},{"key":"10391_CR24","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/s41573-023-00671-z","volume":"22","author":"Y Cao","year":"2023","unstructured":"Cao Y, Langer R, Ferrara N (2023) Targeting angiogenesis in oncology, ophthalmology and beyond. Nat Rev Drug Discov 22:476\u2013495. https:\/\/doi.org\/10.1038\/s41573-023-00671-z","journal-title":"Nat Rev Drug Discov"},{"key":"10391_CR25","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.3390\/ijms22073765","volume":"22","author":"F Lopes-Coelho","year":"2021","unstructured":"Lopes-Coelho F, Martins F, Pereira SA, Serpa J (2021) Anti-angiogenic therapy: current challenges and future perspectives. Int J Mol Sci 22:3765","journal-title":"Int J Mol Sci"},{"key":"10391_CR26","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s43018-022-00491-x","volume":"4","author":"S Garcia-Recio","year":"2023","unstructured":"Garcia-Recio S et al (2023) Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. Nat Cancer 4:128\u2013147. https:\/\/doi.org\/10.1038\/s43018-022-00491-x","journal-title":"Nat Cancer"},{"key":"10391_CR27","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1186\/s12967-021-03113-9","volume":"19","author":"I Schlam","year":"2021","unstructured":"Schlam I et al (2021) The tumor immune microenvironment of primary and metastatic HER2\u2009\u2013\u2009positive breast cancers utilizing gene expression and spatial proteomic profiling. J Translational Med 19:480. https:\/\/doi.org\/10.1186\/s12967-021-03113-9","journal-title":"J Translational Med"},{"key":"10391_CR28","doi-asserted-by":"publisher","unstructured":"Rozenblit M et al (2020) Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2020-001558","DOI":"10.1136\/jitc-2020-001558"},{"key":"10391_CR29","doi-asserted-by":"publisher","unstructured":"Ma Y et al (2022) Endothelial cells potentially participate in the metastasis of triple-negative breast cancer. J Immunol Res (2022). https:\/\/doi.org\/10.1155\/2022\/5412007","DOI":"10.1155\/2022\/5412007"},{"key":"10391_CR30","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1111\/tbj.13684","volume":"26","author":"MK Srour","year":"2020","unstructured":"Srour MK et al (2020) Gene expression comparison between primary triple-negative breast cancer and paired axillary and sentinel lymph node metastasis. Breast J 26:904\u2013910. https:\/\/doi.org\/10.1111\/tbj.13684","journal-title":"Breast J"},{"key":"10391_CR31","doi-asserted-by":"publisher","first-page":"2205395","DOI":"10.1002\/advs.202205395","volume":"10","author":"Y-M Liu","year":"2023","unstructured":"Liu Y-M et al (2023) Combined single-cell and spatial transcriptomics reveal the metabolic evolvement of breast cancer during early dissemination. Adv Sci 10:2205395. https:\/\/doi.org\/10.1002\/advs.202205395","journal-title":"Adv Sci"},{"key":"10391_CR32","doi-asserted-by":"publisher","unstructured":"Kaur J et al (2022) Distinct gene expression profiles of matched primary and metastatic triple-negative breast cancers. Cancers (Basel) 14. https:\/\/doi.org\/10.3390\/cancers14102447","DOI":"10.3390\/cancers14102447"},{"key":"10391_CR33","doi-asserted-by":"publisher","first-page":"101149","DOI":"10.1016\/j.drup.2024.101149","volume":"77","author":"C Qiu","year":"2024","unstructured":"Qiu C et al (2024) RGS5\u2009+\u2009lymphatic endothelial cells facilitate metastasis and acquired drug resistance of breast cancer through oxidative stress-sensing mechanism. Drug Resist Updates 77:101149. https:\/\/doi.org\/10.1016\/j.drup.2024.101149","journal-title":"Drug Resist Updates"},{"key":"10391_CR34","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.3390\/cancers12051270","volume":"12","author":"S Libring","year":"2020","unstructured":"Libring S et al (2020) The dynamic relationship of breast cancer cells and fibroblasts in fibronectin accumulation at primary and metastatic tumor sites. Cancers 12:1270","journal-title":"Cancers"},{"key":"10391_CR35","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1158\/1541-7786.Mcr-18-0151","volume":"16","author":"A Shinde","year":"2018","unstructured":"Shinde A et al (2018) Autocrine fibronectin inhibits breast cancer metastasis. Mol Cancer Res 16:1579\u20131589. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-18-0151","journal-title":"Mol Cancer Res"},{"key":"10391_CR36","doi-asserted-by":"publisher","first-page":"12418","DOI":"10.18632\/oncotarget.2628","volume":"5","author":"J Femel","year":"2014","unstructured":"Femel J et al (2014) Therapeutic vaccination against fibronectin ED-A attenuates progression of metastatic breast cancer. Oncotarget 5:12418\u201312427. https:\/\/doi.org\/10.18632\/oncotarget.2628","journal-title":"Oncotarget"},{"key":"10391_CR37","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/his.12300","volume":"64","author":"B Fernandez-Garcia","year":"2014","unstructured":"Fernandez-Garcia B et al (2014) Expression and prognostic significance of fibronectin and matrix metalloproteases in breast cancer metastasis. Histopathology 64:512\u2013522. https:\/\/doi.org\/10.1111\/his.12300","journal-title":"Histopathology"},{"key":"10391_CR38","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/cells9010027","volume":"9","author":"T-C Lin","year":"2020","unstructured":"Lin T-C et al (2020) Fibronectin in cancer: friend or foe. Cells 9:27","journal-title":"Cells"},{"key":"10391_CR39","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1387\/ijdb.103243eo","volume":"55","author":"E Van Obberghen-Schilling","year":"2011","unstructured":"Van Obberghen-Schilling E et al (2011) Fibronectin and tenascin-C: accomplices in vascular morphogenesis during development and tumor growth. Int J Dev Biol 55:511\u2013525. https:\/\/doi.org\/10.1387\/ijdb.103243eo","journal-title":"Int J Dev Biol"},{"key":"10391_CR40","doi-asserted-by":"publisher","unstructured":"Resnikoff HA, Schwarzbauer JE (2024) Increased basal fibronectin is sufficient to promote excess endothelial cell matrix assembly causing localized barrier dysfunction. Mol Biol Cell 35(ar120). https:\/\/doi.org\/10.1091\/mbc.E24-02-0090","DOI":"10.1091\/mbc.E24-02-0090"},{"key":"10391_CR41","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.bbamcr.2008.11.016","volume":"1793","author":"E Leclerc","year":"2009","unstructured":"Leclerc E, Fritz G, Vetter SW, Heizmann CW (2009) Binding of S100 proteins to RAGE: an update. Biochim Et Biophys Acta (BBA) Mol Cell Res 1793:993\u20131007. https:\/\/doi.org\/10.1016\/j.bbamcr.2008.11.016","journal-title":"Biochim Et Biophys Acta (BBA) Mol Cell Res"},{"key":"10391_CR42","doi-asserted-by":"publisher","unstructured":"Michetti F et al (2023) The S100B protein: a multifaceted pathogenic factor more than a biomarker. Int J Mol Sci 24. https:\/\/doi.org\/10.3390\/ijms24119605","DOI":"10.3390\/ijms24119605"},{"key":"10391_CR43","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1038\/onc.2016.324","volume":"36","author":"T Kwak","year":"2017","unstructured":"Kwak T et al (2017) Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasis. Oncogene 36:1559\u20131572. https:\/\/doi.org\/10.1038\/onc.2016.324","journal-title":"Oncogene"},{"key":"10391_CR44","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41419-020-2432-1","volume":"11","author":"M-C Chen","year":"2020","unstructured":"Chen M-C et al (2020) RAGE acts as an oncogenic role and promotes the metastasis of human lung cancer. Cell Death Dis 11:265. https:\/\/doi.org\/10.1038\/s41419-020-2432-1","journal-title":"Cell Death Dis"},{"key":"10391_CR45","doi-asserted-by":"publisher","unstructured":"Coser M, Neamtu BM, Pop B, Cipaian CR, Crisan M (2025) RAGE and its ligands in breast cancer progression and metastasis. Oncol Rev. https:\/\/doi.org\/10.3389\/or.2024.1507942","DOI":"10.3389\/or.2024.1507942"},{"key":"10391_CR46","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3892\/ijo.2017.4226","volume":"52","author":"MC Yen","year":"2018","unstructured":"Yen MC et al (2018) S100B expression in breast cancer as a predictive marker for cancer metastasis. Int J Oncol 52:433\u2013440. https:\/\/doi.org\/10.3892\/ijo.2017.4226","journal-title":"Int J Oncol"},{"key":"10391_CR47","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1007\/s00125-004-1392-9","volume":"47","author":"JV Valencia","year":"2004","unstructured":"Valencia JV, Mone M, Koehne C, Rediske J, Hughes TE (2004) Binding of receptor for advanced glycation end products (RAGE) ligands is not sufficient to induce inflammatory signals: lack of activity of endotoxin-free albumin-derived advanced glycation end products. Diabetologia 47:844\u2013852. https:\/\/doi.org\/10.1007\/s00125-004-1392-9","journal-title":"Diabetologia"},{"key":"10391_CR48","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2337\/diacare.28.2.379","volume":"28","author":"L Feng","year":"2005","unstructured":"Feng L et al (2005) Chronic vascular inflammation in patients with type 2 diabetes: endothelial biopsy and RT-PCR analysis. Diabetes Care 28:379\u2013384. https:\/\/doi.org\/10.2337\/diacare.28.2.379","journal-title":"Diabetes Care"},{"key":"10391_CR49","doi-asserted-by":"publisher","unstructured":"Sorci G et al (2010) S100B protein, a damage-associated molecular pattern protein in the brain and heart, and beyond. Cardiovasc Psychiatry Neurol. https:\/\/doi.org\/10.1155\/2010\/656481","DOI":"10.1155\/2010\/656481"},{"key":"10391_CR50","doi-asserted-by":"publisher","unstructured":"Kulasinghe A et al (2022) Spatial profiling identifies prognostic features of response to adjuvant therapy in triple negative breast cancer (TNBC). Front Oncol 11\u20132021. https:\/\/doi.org\/10.3389\/fonc.2021.798296","DOI":"10.3389\/fonc.2021.798296"},{"key":"10391_CR51","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1172\/jci96313","volume":"129","author":"T Gruosso","year":"2019","unstructured":"Gruosso T et al (2019) Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. J Clin Invest 129:1785\u20131800. https:\/\/doi.org\/10.1172\/jci96313","journal-title":"J Clin Invest"},{"key":"10391_CR52","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1093\/annonc\/mdy399","volume":"29","author":"B Szekely","year":"2018","unstructured":"Szekely B et al (2018) Immunological differences between primary and metastatic breast cancer. Ann Oncol 29:2232\u20132239. https:\/\/doi.org\/10.1093\/annonc\/mdy399","journal-title":"Ann Oncol"},{"key":"10391_CR53","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1038\/s41467-023-37806-0","volume":"14","author":"JM Carter","year":"2023","unstructured":"Carter JM et al (2023) Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer. Nat Commun 14:2215. https:\/\/doi.org\/10.1038\/s41467-023-37806-0","journal-title":"Nat Commun"},{"key":"10391_CR54","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1158\/0008-5472.Can-11-3768","volume":"72","author":"C P\u00e9queux","year":"2012","unstructured":"P\u00e9queux C et al (2012) Stromal Estrogen receptor-\u03b1 promotes tumor growth by normalizing an increased angiogenesis. Cancer Res 72:3010\u20133019. https:\/\/doi.org\/10.1158\/0008-5472.Can-11-3768","journal-title":"Cancer Res"},{"key":"10391_CR55","doi-asserted-by":"publisher","first-page":"798296","DOI":"10.3389\/fonc.2021.798296","volume":"11","author":"A Kulasinghe","year":"2021","unstructured":"Kulasinghe A et al (2021) Spatial profiling identifies prognostic features of response to adjuvant therapy in triple negative breast cancer (TNBC). Front Oncol 11:798296. https:\/\/doi.org\/10.3389\/fonc.2021.798296","journal-title":"Front Oncol"},{"key":"10391_CR56","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41586-023-06498-3","volume":"621","author":"XQ Wang","year":"2023","unstructured":"Wang XQ et al (2023) Spatial predictors of immunotherapy response in triple-negative breast cancer. Nature 621:868\u2013876. https:\/\/doi.org\/10.1038\/s41586-023-06498-3","journal-title":"Nature"},{"key":"10391_CR57","doi-asserted-by":"publisher","first-page":"6598","DOI":"10.1038\/s41598-020-63539-x","volume":"10","author":"RL Stewart","year":"2020","unstructured":"Stewart RL, Matynia AP, Factor RE, Varley KE (2020) Spatially-resolved quantification of proteins in triple negative breast cancers reveals differences in the immune microenvironment associated with prognosis. Sci Rep 10:6598. https:\/\/doi.org\/10.1038\/s41598-020-63539-x","journal-title":"Sci Rep"},{"key":"10391_CR58","doi-asserted-by":"publisher","first-page":"1367875","DOI":"10.3389\/fimmu.2024.1367875","volume":"15","author":"P Leone","year":"2024","unstructured":"Leone P et al (2024) Endothelial cells in tumor microenvironment: insights and perspectives. Front Immunol 15:1367875. https:\/\/doi.org\/10.3389\/fimmu.2024.1367875","journal-title":"Front Immunol"},{"key":"10391_CR59","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson MD, McCarthy DJ, Smyth GK (2010) EdgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26:139\u2013140. https:\/\/doi.org\/10.1093\/bioinformatics\/btp616","journal-title":"Bioinformatics"}],"container-title":["Clinical &amp; Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-026-10391-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-026-10391-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-026-10391-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T16:03:49Z","timestamp":1768838629000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-026-10391-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["10391"],"URL":"https:\/\/doi.org\/10.1007\/s10585-026-10391-4","relation":{},"ISSN":["1573-7276"],"issn-type":[{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"23 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11"}}